Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Allakos Inc. ALLK
$4.49
+$0.36 (7.93%)
На 18:01, 12 мая 2023
+4 755.23%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
366150086.00000000
-
week52high
8.73
-
week52low
2.54
-
Revenue
0
-
P/E TTM
-1
-
Beta
0.43527000
-
EPS
-5.12000000
-
Last Dividend
0.00000000
-
Next Earnings Date
04 мая 2023 г. в 10:59
Описание компании
Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and/or eosinophilic duodenitis; a Phase II/III study for eosinophilic esophagitis; and a Phase II clinical study to atopic dermatitis and chronic spontaneous urticaria. It is also developing lirentelimab (AK002) for the treatment of mast cell gastrointestinal disease, chronic urticaria, severe allergic conjunctivitis, and indolent systemic mastocytosis; and AK006 to treat allergic and inflammatory diseases. The company was incorporated in 2012 and is headquartered in Redwood City, California.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Goldman Sachs | Neutral | Neutral | 24 мая 2022 г. |
| SVB Leerink | Market Perform | Market Perform | 12 мая 2022 г. |
| Barclays | Underweight | Underweight | 11 мая 2022 г. |
| Morgan Stanley | Equal-Weight | Equal-Weight | 10 мая 2022 г. |
| SVB Leerink | Market Perform | Market Perform | 16 февр 2022 г. |
| Cantor Fitzgerald | Overweight | Overweight | 12 сент 2022 г. |
| Morgan Stanley | Equal-Weight | Equal-Weight | 27 янв 2023 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Alexander Robert | A | 462325 | 462325 | 06 янв 2023 г. |
| Alexander Robert | A | 1056694 | 301575 | 06 янв 2023 г. |
| Paterson Craig A. | A | 157428 | 157428 | 06 янв 2023 г. |
| Paterson Craig A. | A | 372474 | 102690 | 06 янв 2023 г. |
| Tomasi Adam | A | 300471 | 300471 | 06 янв 2023 г. |
| Tomasi Adam | A | 744734 | 195997 | 06 янв 2023 г. |
| Radford Harlan Baird | A | 194144 | 194144 | 06 янв 2023 г. |
| Radford Harlan Baird | A | 398901 | 126640 | 06 янв 2023 г. |
| Tomasi Adam | D | 548737 | 9783 | 02 дек 2022 г. |
| Alexander Robert | D | 755119 | 15152 | 02 дек 2022 г. |
Новостная лента
Why Allakos Stock Was Heating Up Today
The Motley Fool
07 мар 2023 г. в 16:05
Allakos is barreling toward two mid-stage data readouts that could alter its long-term outlook. An analyst thinks these twin catalysts could cause the biotech's shares to more than quadruple in value.
Allakos Inc. (ALLK) Moves to Buy: Rationale Behind the Upgrade
Zacks Investment Research
09 дек 2022 г. в 13:33
Allakos Inc. (ALLK) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Allakos: Potential For Comeback With Lirentelimab With 2 Indications
Seeking Alpha
18 окт 2022 г. в 03:22
Results from the phase 2b study, using lirentelimab for the treatment of patients with chronic spontaneous urticaria, are expected in the 2nd half of 2023. Xolair naive CSU cohort of 13 patients started with an average UAS7 score of 18.5 points at baseline and at week 22 dropped down to 4.6 points.
Alkermes, Allakos See Activist Action
Market Watch
14 окт 2022 г. в 18:35
These disclosures are from 13Ds filed with the Securities and Exchange Commission. 13Ds are filed within 10 days of an entity's attaining more than 5% in any class of a company's securities.
3 Healthcare Stocks to Sell Before They Die
InvestorPlace
30 сент 2022 г. в 11:48
The Fed's key interest rate target now stands at 3%-3.25%, way up from 0%-0.25% at the beginning of the year. That means, for all companies, borrowing money is becoming much more expensive.